Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | SNDX-6352 |
Synonyms | |
Therapy Description |
Axatilimab (SNDX-6352) is a humanized monoclonal antibody against colony-stimulating factor-1 receptor (CSF-1R), which may enhance anti-tumor immune response (SITC Meeting, Nov 2017, abstract P505). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SNDX-6352 | SNDX 6352|SNDX6352|UCB6352|Axatilimab | CSF1R Antibody 5 | Axatilimab (SNDX-6352) is a humanized monoclonal antibody against colony-stimulating factor-1 receptor (CSF-1R), which may enhance anti-tumor immune response (SITC Meeting, Nov 2017, abstract P505). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03238027 | Phase I | SNDX-6352 Durvalumab + SNDX-6352 | A Phase 1, Open-label, Dose Escalation Trial to Investigate SNDX-6352 in Patients With Solid Tumors | Completed | USA | 0 |